ストックスクリーナーアプリを入手
1.01
0.98%
-0.01
アフターアワーズ：
1.01
前日終値:
$1.02
開ける：
$1.02
24時間の取引高:
301.45K
Relative Volume:
0.78
時価総額：
$62.50M
収益：
-
当期純損益:
$-60.36M
株価収益率:
-0.2299
EPS:
-4.394
ネットキャッシュフロー:
$-15.05M
1週間 パフォーマンス:
-0.98%
1か月 パフォーマンス:
-27.34%
6か月 パフォーマンス:
-66.89%
1年 パフォーマンス:
-81.19%
1日の値動き範囲:
$0.99
$1.04
1週間の範囲:
$0.988
$1.07
52週間の値動き範囲:
$0.97
$5.50
Zura Bio Ltd Stock (ZURA) Company Profile
ZURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.01 | 63.11M | 0 | -60.36M | -15.05M | -4.394 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-04 | 開始されました | Leerink Partners | Outperform |
| 2024-09-05 | 開始されました | H.C. Wainwright | Neutral |
| 2024-05-03 | 開始されました | Piper Sandler | Overweight |
| 2023-10-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-08-25 | 開始されました | Oppenheimer | Outperform |
| 2023-06-22 | 開始されました | Guggenheim | Buy |
| 2023-06-14 | 開始されました | Chardan Capital Markets | Buy |
| 2023-05-24 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Zura Bio Ltd (ZURA) 最新ニュース
Northern Trust Corp Has $1.01 Million Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts - Defense World
Zura Bio to Present at the Jefferies Global Healthcare Conference - Yahoo Finance
Zura Bio shareholders approve board nominees and auditor - Investing.com Australia
Zura Bio shareholders approve board nominees and auditor By Investing.com - Investing.com South Africa
Q1 Earnings Forecast for Zura Bio Issued By HC Wainwright - Defense World
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment - Investing.com Australia
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment By Investing.com - Investing.com India
Zura Bio (ZURA) Initiates Phase 2 Study for Tibulizumab in HS Treatment | ZURA Stock News - GuruFocus
Cubist Systematic Strategies LLC Makes New $62,000 Investment in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa - Quantisnow
Dimensional Fund Advisors LP Acquires New Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Wells Fargo & Company MN Grows Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Barclays PLC Boosts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Raymond James Financial Inc. Invests $371,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $17.00 - Defense World
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheime - GuruFocus
ZURA: Oppenheimer Revises Price Target Amid Ongoing Trials | ZUR - GuruFocus
ZURA Stock Rating Maintained; Price Target Lowered by Oppenheimer | ZURA Stock News - GuruFocus
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Yahoo Finance
Ratio Analysis: Unpacking Zura Bio Ltd (ZURA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Zura Bio Ltd Inc. (ZURA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Do investors need to be concerned about Zura Bio Ltd (ZURA)? - uspostnews.com
Geode Capital Management LLC Increases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Yahoo
ZURA overperforms with a 8.76 increase in share price - uspostnews.com
Zura Bio Limited (NASDAQ:ZURA) Receives $14.67 Average Price Target from Analysts - Defense World
HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings - Defense World
HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00 - Defense World
ZURA stock touches 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating - Investing.com Australia
ZURA stock touches 52-week low at $1.07 amid market challenges - Investing.com
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating By Investing.com - Investing.com South Africa
Insiders' US$1.01m Investments In Red Following Zura Bio's US$21m Dip In Market Value - simplywall.st
Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio - Defense World
Zura Bio (NASDAQ:ZURA) Price Target Lowered to $10.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Chardan cuts Zura Bio stock target to $10, keeps buy rating By Investing.com - Investing.com South Africa
Chardan cuts Zura Bio stock target to $10, keeps buy rating - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target By Investing.com - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target - Investing.com
Leerink maintains $12 target on Zura Bio stock post-earnings By Investing.com - Investing.com Australia
Leerink maintains $12 target on Zura Bio stock post-earnings - Investing.com
Zura Bio Ltd expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Consensus Price Target from Analysts - Defense World
Rhumbline Advisers Has $94,000 Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
(Bi-)specific gravity: Bambusa, others serious about approach - BioWorld MedTech
Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Can Zura Bio's Novel Dual-Pathway Antibodies Transform Autoimmune Treatment? Key Updates Coming - Stock Titan
Zura Bio Ltd (ZURA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):